Novel and emerging therapies for B cell lymphoma

por Ayyappan, Sabarish, Maddocks, Kami
Publicado 2019

Profile of Polatuzumab Vedotin in the Treatment of Patients with Relapsed/Refractory Non-Hodgkin Lymphoma: A Brief Report on the Emerging Clinical Data

por Sawalha, Yazeed, Maddocks, Kami
Publicado 2020

Update in the management of chronic lymphocytic leukemia

por Maddocks, Kami J, Lin, Thomas S
Publicado 2009

What's new in the management of chronic lymphocytic leukemia? 2008 ASH Review (New York Medical College, January 31, 2009)

por Maddocks, Kami J, Lin, Thomas S
Publicado 2009

Clinical Treatment Guidelines for Tafasitamab plus Lenalidomide in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

por Nedved, Adrienne, Maddocks, Kami, Nowakowski, Grzegorz S
Publicado 2023

Relapsed Mantle Cell Lymphoma: Current Management, Recent Progress, and Future Directions

por Bond, David A, Martin, Peter, Maddocks, Kami J
Publicado 2021

Febrile Hypotensive Reactions Following ABVD Chemotherapy in Patients With EBV-associated Classical Hodgkin Lymphoma

por Bond, David A., Dotson, Emily, Awan, Farrukh T., Baiocchi, Robert A., Blum, Kristie A., Maddocks, Kami
Publicado 2019

Safety, tolerability, and preliminary activity of IMGN529, a CD37-targeted antibody-drug conjugate, in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: a dose-esca...

por Stathis, Anastasios, Flinn, Ian W., Madan, Sumit, Maddocks, Kami, Freedman, Arnold, Weitman, Steven, Zucca, Emanuele, Munteanu, Mihaela C., Lia Palomba, M.
Publicado 2018

miR-155 expression is associated with chemoimmunotherapy outcome and is modulated by Bruton's tyrosine kinase inhibition with Ibrutinib.

por Guinn, Daphne, Ruppert, Amy S., Maddocks, Kami, Jaglowski, Samantha, Gordon, Amber, Lin, Thomas S., Larson, Richard, Marcucci, Guido, Hertlein, Erin, Woyach, Jennifer, Johnson, Amy J., Byrd, John C.
Publicado 2014

Outcomes of patients with diffuse large B-cell and high-grade B-cell lymphomas with synchronous CNS and systemic involvement at diagnosis treated with high-dose methotrexate and R-...

por Fleming, Megan, Huang, Ying, Dotson, Emily, Bond, David A., Reneau, John, Epperla, Narendranath, Alinari, Lapo, Brammer, Jonathan, Christian, Beth, Baiocchi, Robert A., Maddocks, Kami, Sawalha, Yazeed
Publicado 2022

Treatment of primary mediastinal B-cell lymphoma with dose-adjusted REPOCH during pregnancy

por Annunzio, Kaitlin, Cackovic, Michael, Bond, David, Sawalha, Yazeed, Voorhees, Timothy J., Hanel, Walter, Alinari, Lapo, Baiocchi, Robert, Reneau, John, Brammer, Jonathan, Maddocks, Kami, Christian, Beth, Epperla, Narendranath
Publicado 2022

Feasibility of high-dose methotrexate administered on day 1 of (R)CHOP in aggressive non-Hodgkin lymphomas

por Fleming, Megan, Huang, Ying, Dotson, Emily, Bond, David A., Reneau, John, Epperla, Narendranath, Alinari, Lapo, Brammer, Jonathan, Christian, Beth A., Baiocchi, Robert A., Maddocks, Kami, Sawalha, Yazeed
Publicado 2022

Impact of circulating lymphoma cells at diagnosis on outcomes in patients with Waldenstrom macroglobulinemia

por Nalin, Ansel, Zhao, Qiuhong, Voorhees, Timothy, Bond, David, Sawalha, Yazeed, Hanel, Walter, Sigmund, Audrey, Annunzio, Kaitlin, Alinari, Lapo, Baiocchi, Robert, Maddocks, Kami, Jones, Dan, Christian, Beth, Epperla, Narendranath
Publicado 2023

Acalabrutinib for treatment of diffuse large B-cell lymphoma: results from a phase Ib study

por Strati, Paolo, de Vos, Sven, Ruan, Jia, Maddocks, Kami J., Flowers, Christopher R., Rule, Simon, Patel, Priti, Xu, Yan, Wei, Helen, Frigault, Melanie M., Calvo, Roser, Dyer, Martin J.S.
Publicado 2021

The regulation of tumor‐suppressive microRNA, miR‐126, in chronic lymphocytic leukemia

por Guinn, Daphne, Lehman, Amy, Fabian, Catherine, Yu, Lianbo, Maddocks, Kami, Andritsos, Leslie A., Jones, Jeffrey A., Flynn, Joseph M., Jaglowski, Samantha M., Woyach, Jennifer A., Byrd, John C., Johnson, Amy J.
Publicado 2017

PB2304: FIVE-YEAR SUBGROUP ANALYSIS OF TAFASITAMAB + LENALIDOMIDE FROM THE PHASE II L-MIND STUDY IN PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA

por Duell, Johannes, Abrisqueta, Pau, Dreyling, Martin, Gaidano, Gianluca, Barca, Eva González, Jurczak, Wojciech, Liberati, Anna Marina, Maddocks, Kami, Menne, Tobias, Nagy, Zsolt, Tournilhac, Olivier, Bakuli, Abhishek, Amin, Aasim, Gurbanov, Konstantin, Salles, Gilles
Publicado 2023

P618: LONG-TERM SAFETY WITH ≥12 MONTHS OF PIRTOBRUTINIB IN RELAPSED/REFRACTORY (R/R) B-CELL MALIGNANCIES

por Jurczak, Wojciech, Coombs, Catherine C., Shah, Nirav N., Woyach, Jennifer, Cheah, Chan Y., Patel, Krish, Maddocks, Kami, Wang, Yucai, E. Muehlenbein, Catherine, Wang, Chunxiao, Abhyankar, Sarang, Tsai, Donald E., Eyre, Toby A.
Publicado 2023

P112: Phase II Trial of Brentuximab Vedotin plus ibrutinib in Relapsed/Refractory Hodgkin Lymphoma

por Mei, Matthew, Palmer, Joycelynne, Maddocks, Kami, Martin, Peter, Tsai, Ni-Chun, Smith, Eileen, Popplewell, Leslie, Armenian, Saro, Shouse, Geoffrey, Chen, Robert, Kwak, Larry, Rosen, Steven T., Forman, Stephen, Bond, David, Herrera, Alex F.
Publicado 2022

Treatment Outcomes and Roles of Transplantation and Maintenance Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma: Results From Large Real-World Cohorts

por Martin, Peter, Cohen, Jonathon B., Wang, Michael, Kumar, Anita, Hill, Brian, Villa, Diego, Switchenko, Jeffrey M., Kahl, Brad, Maddocks, Kami, Grover, Natalie S., Qi, Keqin, Parisi, Lori, Daly, Katherine, Zhu, Angeline, Salles, Gilles
Publicado 2023

Dinaciclib is a Novel Cyclin Dependent Kinase Inhibitor with Significant Clinical Activity in Relapsed and Refractory Chronic Lymphocytic Leukemia

por Flynn, Joseph, Jones, Jeffrey, Johnson, Amy J., Andritsos, Leslie, Maddocks, Kami, Jaglowski, Samantha, Hessler, Joshua, Grever, Michael R., Ellie, Im, Zhou, Honghong, Zhu, Yali, Zhang, Da, Small, Karen, Bannerji, Rajat, Byrd, John C.
Publicado 2015